ArticleMolecular neurobiology2025
Serum Inflammatory Factors Levels and Risk of Myasthenia Gravis: A Bidirectional Mendelian Randomization Study.
Article in Molecular neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Myasthenia gravis (MG) is an autoimmune disorder characterized by muscle weakness, where the role of inflammatory processes remains incompletely understood. Bidirectional Mendelian randomization (MR) provides a method to explore potential causal relationships between traits. In this bidirectional MR study, we investigated the relationship between 40 serum inflammatory factors and MG using the two-sample MR approach. The inverse variance weighted (IVW) method was the primary analytical method. Factors with P < 0.05 after false discovery rate (FDR) correction were considered to have a significant causal relationship with MG. Bayesian colocalization and functional mapping were employed to further analyze the instrumental variables. We then used reverse MR to examine potential reverse causality and validated these findings in the UK Biobank-PPP cohort. A phenome-wide association study (PheWAS) was conducted using UK Biobank and FinnGen data to evaluate the potential side effects of targeting these inflammatory factors as therapeutic interventions. Our results indicated that elevated levels of serum interleukin-10 (IL-10) were associated with a decreased risk of MG (P = 9.34E-03, OR [95% CI] = 0.52 [0.33-0.85]). Reverse MR revealed no evidence of reverse causality (P > 0.05), with further validation in the UK Biobank-PPP cohort (P = 3.81E-3, OR [95% CI] = 5.43E-02 [7.54E-03-3.91E-01]). The PheWAS outcomes showed associations of serum IL-10 levels across a broad phenotypic spectrum. Our findings suggest that IL-10 may play a protective role in the pathogenesis of MG. The absence of reverse causality highlights IL-10 as a potential therapeutic target. This study emphasizes the importance of inflammatory factors in autoimmune disorders and supports the utility of MR studies in uncovering novel therapeutic targets.
Indexed as
Identifiers
39932515What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.